Clinical Trial Update: Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL [Phase 2]

View source ↗

Summary

Phase 2 study evaluating acalabrutinib in combination with rituximab for untreated, elderly and/or frail patients with diffuse large B-cell lymphoma is currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• Rituxan (rituximab)

Snippet

Sponsor: AstraZeneca | Conditions: Diffuse Large B-Cell Lymphoma | Phase 2 | Status: RECRUITING